KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Neogenomics (NEO) over the last 16 years, with Q4 2025 value amounting to $9000.0.

  • Neogenomics' Amortization of Deferred Charges fell 8125.0% to $9000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $87000.0, marking a year-over-year decrease of 5396.83%. This contributed to the annual value of $87000.0 for FY2025, which is 5396.83% down from last year.
  • As of Q4 2025, Neogenomics' Amortization of Deferred Charges stood at $9000.0, which was down 8125.0% from $9000.0 recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Amortization of Deferred Charges registered a high of $48000.0 during Q4 2024, and its lowest value of $9000.0 during Q3 2025.
  • For the 5-year period, Neogenomics' Amortization of Deferred Charges averaged around $41050.0, with its median value being $46000.0 (2022).
  • Per our database at Business Quant, Neogenomics' Amortization of Deferred Charges soared by 7307.69% in 2021 and then tumbled by 8125.0% in 2025.
  • Over the past 5 years, Neogenomics' Amortization of Deferred Charges (Quarter) stood at $45000.0 in 2021, then grew by 2.22% to $46000.0 in 2022, then changed by 0.0% to $46000.0 in 2023, then grew by 4.35% to $48000.0 in 2024, then tumbled by 81.25% to $9000.0 in 2025.
  • Its last three reported values are $9000.0 in Q4 2025, $9000.0 for Q3 2025, and $21000.0 during Q2 2025.